Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.

Responsive image

Suvorexant

Suvorexant
Clinical data
Trade namesBelsomra
Other namesMK-4305; MK4305
AHFS/Drugs.comMonograph
MedlinePlusa614046
License data
Pregnancy
category
Dependence
liability		Low
Addiction
liability		Low
Routes of
administration		By mouth[2]
Drug classOrexin receptor antagonist; Hypnotic; Sedative
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability82% (10 mg; lower at higher doses)[2][5]
Protein binding99.5%[6][2]
MetabolismLiver (CYP3A major, CYP2C19 minor)[2]
MetabolitesHydroxysuvorexant (inactive)[2]
Elimination half-life12.2 hours (8–19 hours) (40 mg)[2][5][7]
ExcretionFeces: 66%[2]
Urine: 23%[2]
Identifiers
  • [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.210.546 Edit this at Wikidata
Chemical and physical data
FormulaC23H23ClN6O2
Molar mass450.93 g·mol−1
3D model (JSmol)
  • C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl
  • InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1 checkY
  • Key:JYTNQNCOQXFQPK-MRXNPFEDSA-N checkY
  (verify)

Suvorexant, sold under the brand name Belsomra, is an orexin antagonist medication which is used in the treatment of insomnia.[2][6] It is indicated specifically for the treatment of insomnia characterized by difficulties with sleep onset and/or maintenance in adults.[2][6] Suvorexant helps with falling asleep faster, sleeping longer, being awake less in the middle of the night, and having better quality of sleep.[2][8] Its effectiveness is modest,[9] and is similar to that of other orexin antagonists, but is lower than that of benzodiazepines and Z-drugs.[10] Suvorexant is taken by mouth.[2][11][6]

Side effects of suvorexant include somnolence, daytime sleepiness and sedation, headache, dizziness, abnormal dreams, dry mouth, and impaired next-day driving ability.[2][8][12] Rarely, sleep paralysis, sleep-related hallucinations, complex sleep behaviors like sleepwalking, and suicidal ideation may occur.[2][6][9] Tolerance, dependence, withdrawal, and rebound effects do not appear to occur significantly with the medication.[2][13][14] Suvorexant is a dual orexin receptor antagonist (DORA).[6] It acts as a selective dual antagonist of the orexin OX1 and OX2 receptors.[6] The medication has an intermediate elimination half-life of 12 hours and a time to peak of about 2 to 3 hours.[2][6] Unlike benzodiazepines and Z-drugs, suvorexant does not interact with GABA receptors, instead having a distinct mechanism of action.[6][15]

Clinical development of suvorexant began in 2006[16] and it was introduced for medical use in 2014.[2][17] The medication is a schedule IV controlled substance in the United States and may have a modest potential for misuse.[18][2][19] In other places, such as Australia, suvorexant is a prescription-only medicine and is not a controlled drug.[1] Suvorexant is not available in generic formulations.[11][20][21] Besides suvorexant, other orexin receptor antagonists like lemborexant and daridorexant have also been introduced.[22][23]

  1. ^ a b Cite error: The named reference Belsomra-AU-Label was invoked but never defined (see the help page).
  2. ^ a b c d e f g h i j k l m n o p q r s "Belsomra- suvorexant tablet, film coated". DailyMed. Retrieved 30 January 2020.
  3. ^ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  4. ^ "Regulatory Decision Summary for Belsomra". 23 October 2014.
  5. ^ a b Cite error: The named reference MerckSharpDohme2013 was invoked but never defined (see the help page).
  6. ^ a b c d e f g h i Jacobson LH, Callander GE, Hoyer D (November 2014). "Suvorexant for the treatment of insomnia". Expert Review of Clinical Pharmacology. 7 (6): 711–730. doi:10.1586/17512433.2014.966813. PMID 25318834. S2CID 41099462.
  7. ^ Cite error: The named reference DimovaBrarMen2014 was invoked but never defined (see the help page).
  8. ^ a b Cite error: The named reference pmid28365447 was invoked but never defined (see the help page).
  9. ^ a b Cite error: The named reference pmid26648692 was invoked but never defined (see the help page).
  10. ^ Cite error: The named reference pmid35843245 was invoked but never defined (see the help page).
  11. ^ a b Cite error: The named reference Drugs.com-Belsomra-Generic was invoked but never defined (see the help page).
  12. ^ Kishi T, Matsunaga S, Iwata N (2015). "Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials". PLOS ONE. 10 (8): e0136910. Bibcode:2015PLoSO..1036910K. doi:10.1371/journal.pone.0136910. PMC 4552781. PMID 26317363.
  13. ^ Cite error: The named reference pmid28994603 was invoked but never defined (see the help page).
  14. ^ Cite error: The named reference pmid32901578 was invoked but never defined (see the help page).
  15. ^ Atkin T, Comai S, Gobbi G (April 2018). "Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery". Pharmacological Reviews. 70 (2): 197–245. doi:10.1124/pr.117.014381. PMID 29487083. S2CID 3578916.
  16. ^ Cite error: The named reference pmid25406050 was invoked but never defined (see the help page).
  17. ^ Cite error: The named reference APDNews2014 was invoked but never defined (see the help page).
  18. ^ Cite error: The named reference FederalRegister2016 was invoked but never defined (see the help page).
  19. ^ Cite error: The named reference pmid25231363 was invoked but never defined (see the help page).
  20. ^ Cite error: The named reference pmid30092886 was invoked but never defined (see the help page).
  21. ^ Cite error: The named reference pmid26955275 was invoked but never defined (see the help page).
  22. ^ Cite error: The named reference pmid35043499 was invoked but never defined (see the help page).
  23. ^ Cite error: The named reference pmid35298826 was invoked but never defined (see the help page).

Previous Page Next Page






سوفوريكسانت Arabic Suvorexant Catalan Suvorexant German Suvorexant Spanish سوورکسانت FA Suvoreksantti Finnish Suvorexant French Suvorexant Hungarian Suvoreksant ID スボレキサント Japanese

Responsive image

Responsive image